NCT00412022 2023-03-24
HOBOE
National Cancer Institute, Naples
Phase 3 Unknown
Clinical Trials
11 trialsNCT05439499 2022-07-06
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT03625531 2022-04-05
A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS
The First Affiliated Hospital of Guangzhou Medical University
Phase 3 Unknown
NCT04047758 2021-07-20
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
Shengjing Hospital
Phase 3 Unknown
NCT03966898 2021-06-02
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT01758146 2020-03-04
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 3 Unknown
NCT00541086 2020-02-07
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
Gruppo Italiano Mammella (GIM)
Phase 3 Unknown
NCT02769104 2018-01-09
ACCN
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT00688194 2013-08-26
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00902954 2009-05-15
LEANEX
Fudan University
Phase 3 Unknown